Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Harvard Business School
Johnson and Johnson
Express Scripts
McKesson

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,620,795

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,620,795
Title: Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
Abstract:Methods and compositions for producing a mammal capable of expressing an exogenously supplied gene in cells of the airway are disclosed. Lipid carrier-nucleic acid complexes or nucleic acid abre are prepared then delivered via aerosol or systemically to the lung abre or lung plus extrapulmonary tissues. The invention provides a direct method for transforming pulmonary cells as a means for treating the manifestations of CF in the lung and involved extrapulmonary tissues.
Inventor(s): Debs; Robert J. (Mill Valley, CA), Zhu; Ning (El Cerrito, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:09/461,686
Patent Claims:1. A pharmaceutical composition, said composition comprising a mammalian transcription complex in a pharmaceutically acceptable carrier or diluent; said complex comprising a cationic lipid carrier and a plasmid having a transcription or expression cassette comprising a nucleotide sequence encoding a wild-type cystic fibrosis transmembrane conductance regulator protein, wherein said cassette is capable of being expressed to produce said protein in mammalian cells transfected with said cassette; and wherein said lipid carrier comprises cationic and noncationic lipids, and wherein said complex has a ratio of between about 4:1 to 1:10 micrograms DNA to nanomoles cationic lipid; and said complex does not aggregate in vitro.

2. The pharmaceutical composition according to claim 1, wherein said cassette comprises an inducible promoter.

3. The pharmaceutical composition according to claim 2, wherein said inducible promoter is a cell specific promoter, a tissue specific promoter, or a hormone responsive promoter.

4. The pharmaceutical composition according to claim 2, wherein said promoter is a promoter from a cystic fibrosis transmembrane conductance regulator gene.

5. The pharmaceutical composition according to claim 2, wherein said cassette comprises an SV40 enhancer element whereby transcription from said promoter is enhanced.

6. The pharmaceutical composition according to claim 1, wherein said cationic lipid carrier comprises a lipid selected from the group consisting of N[1-(2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA); dimethyl dioctadecyl ammonium bromide (DDAB); 1,2-dioleoyloxy-3-(trimethylammonio) propane (DOTAP); lysinylphosphatidyl-ethanolamine (L-PE); dioleoyl phosphatidylethanolamine (DOPE); and cholesterol (Chol).

7. A method for increasing the amount of pulmonary cystic fibrosis transmembrane conductance regulator (CFTR) activity in a mammal in need thereof, said method comprising administering by inhalation to the lung of said mammal a therapeutically effective amount of a composition according to claim 6.

8. A method according to claim 7, wherein the mammal is a human.

9. A method according to claim 8, wherein said cystic fibrosis transmembrane conductance regulator (CFTR) protein is encoded by a human wild-type nucleotide sequence.

10. A method according to claim 9, wherein said human has cystic fibrosis.

11. The pharmaceutical composition according to claim 1, wherein said cationic lipid carrier comprises cholesterol and a lipid selected from the group consisting of N[1-(2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA); dimethyldioctadecylammoniumbromide (DDAB); 1,2-dioleoyloxy-3-(trimethylammonio)propane (DOTAP); and lysinylphosphatidyl-ethanolamine (L-PE).

12. The pharmaceutical composition according to claim 1, wherein said cationic lipid carrier comprises dioleoyl phosphatidylethanolamine (DOPE) and a lipid selected from the group consisting of N[1-(2,3-dioleyloxy)propyl]-N, N,N-triethylammonium (DOTMA); dimethyldioctadecylammoniumbromide (DDAB); 1,2-dioleoyloxy-3-(trimethylammonio)propane (DOTAP); and lysinylphosphatidyl-ethanolamine (L-PE).

13. The pharmaceutical composition according to claim 1, wherein said cationic lipid carrier is a small unilamellar vesicle and said complex is between about 100 nanometers and 10 microns in diameter.

14. The pharmaceutical composition according to claim 13, wherein said small unilamellar vesicle comprises (a) dioleoyl phosphatidylethanolamine (DOPE) and N[1-(2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA) or (b) dimethyldioctadecyl-ammoniumbromide (DDAB) and cholesterol.

15. The pharmaceutical composition according to claim 1, wherein said cassette comprises an open reading frame nucleic acid sequence encoding a wild-type cystic fibrosis transmembrane conductance regulator protein that is intron-free.

16. The pharmaceutical composition according to claim 1, wherein said cassette comprises an open reading frame nucleic acid sequence encoding a wild-type cystic fibrosis transmembrane conductance regulator protein that has an intron 5' to said open reading frame nucleic acid sequence.

17. The pharmaceutical composition according to claim 1, wherein said cassette comprises an open reading frame nucleic acid sequence encoding a wild-type cystic fibrosis transmembrane conductance regulator protein and has an expanded intron 3' to said open reading frame nucleic acid sequence.

18. The pharmaceutical composition according to claim 1, wherein said pharmaceutically acceptable carrier or diluent is acceptable by intraoral or intranasal administration.

19. The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable carrier or diluent is acceptable for intravenous administration.

20. The pharmaceutical composition according to claim 1, wherein the cystic fibrosis transmembrane conductance regulator (CFTR) protein is encoded by a human wild-type nucleotide sequence.

21. A method for increasing the amount of pulmonary cystic fibrosis transmembrane conductance regulator (CFTR) activity in a mammal in need thereof, said method comprising administering by inhalation to the lung of said mammal a therapeutically effective amount of a composition according to claim 1.

22. A method according to claim 21, wherein the mammal is a human.

23. A method according to claim 22, wherein said cystic fibrosis transmembrane conductance regulator (CFTR) protein is encoded by a human wild-type nucleotide sequence.

24. A method according to claim 22, wherein said human has cystic fibrosis.

25. A lit, said kit comprising: a first container containing a plasmid having a transcription or expression cassette comprising a nucleotide sequence encoding a wild-type cystic fibrosis transmembrane conductance regulator protein and wherein said cassette is capable of being expressed to produce said protein in mammalian cells transfected with said cassette; and a second container containing a specific amount of a cationic lipid carrier comprising cationic and noncationic lipids.

26. A kit according to claim 25, said kit further comprising a nebulizer.

Details for Patent 6,620,795

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The Regents of the University of California (Oakland, CA) 2011-12-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The Regents of the University of California (Oakland, CA) 2011-12-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The Regents of the University of California (Oakland, CA) 2011-12-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKesson
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.